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A hospital based descriptive study was performed during the period of January 2018 to 
December 2018. 62 young colorectal cancer patients attending to Medical Oncology 
Department, YGH, who met the inclusion and exclusion criteria, were involved in this study. 
This study included histologically proved 36 rectal cancer and 26 colon cancer patients. 
Details of patient’s particulars, presenting symptoms, stage, performance status, treatment 
modalities and response to treatment were recorded. The most common clinical presentation 
was abdominal pain in colon cancer and bleeding per rectum and tenesmus in rectal cancer. 
59.68% of patients had undergone curative resection and 40.32% were done palliative 
surgery. 9, 38 and 15 patients were given neoadjuvant, adjuvant and palliative chemotherapy, 
respectively. 27 rectal cancer patients were also treated with radiotherapy. Among 9 patients 
who were treated with neoadjuvant chemotherapy, only one patient had been performed 
curative ARR after neoadjuvant therapy. In 38 patients treated with adjuvant chemotherapy, 
10 patients had locoregional recurrence and 4 patients showed distant recurrence during 
adjuvant chemotherapy. 24 patients had no recurrence until the end of adjuvant 
chemotherapy. In 16 stage IV patients, 1 patient with right ovarian metastasis was treated with 
debulking surgery followed by adjuvant chemotherapy. This patient showed no recurrence 
until the end of study. 15 patients were done palliative surgery followed by palliative 
chemotherapy. 2 patients had partial response and 13 patients were progressive. Most patients 
are symptomatic at the time of presentation, with the majority having rectal bleeding and 
chronic abdominal pain. The majority of tumors were located in the rectum, sigmoid colon 
and ascending colon. The earlier the stage, the more curative surgery and favorable outcome 
occur. Therefore, it was very important to notify the early symptoms of colorectal cancer. 




Colorectal cancer (CRC) is the second most 
common cause of cancer mortality after lung 
cancer in the United States and ranks third in 
frequency among primary sites of cancer in 
both men and women (after lung, breast and 
prostate cancer). Nearly one million cases are 
diagnosed annually worldwide, accounting for 
9% to 10% of human cancers. The lifetime 
estimated risk for developing CRC in United 
States is about 5%, with 3% of CRC occurring 
in patients younger than 40 years of age.1 As a 
disease predominantly affecting older 
individuals, 90% of all CRC have been 
diagnosed in patients more than 50 years of 
age. However, an increasing evidence of CRC 
in patients less than 40 years of age has been 
reported. When confronting young onset CRC 
with older patients, issues such as biological 
aggressiveness, stage at diagnosis and clinical 
outcomes seem to differ in many aspects.2 
According to the Yangon Cancer Registry 
(2016), the numbers of CRC patients enrolled 
at Medical Oncology Unit, Yangon General  
 
Hospital (YGH) are 393 in total 3584 cancer 
patients (10.96%).There are 98 patients under 
the age of 40 years in total 393 of CRC 
patients (24.93%) and 295 patients over the 
age of 40 years (75.06%). Data from the 
American Cancer Society also noticed an 
increase in the global incidence from 1992 to 
2005 among adults between 20 and 49 years, 
demonstrating a 3.5% increase per year 
among men and 2.9% per year in women.3 
The limited studies reveal a wide range of 
reported clinico-pathological characteristics 
and prognosis for young CRC patients. Some 
studies have demonstrated that young CRC 
patients presented poor pathological features 
and advanced stage compared with older 
patients. Nonetheless, others have found no 
difference when tumor stage and pathological 
features were compared with older 
population.4 The purpose of this study is to 
describe the epidemiological, clinical and 
pathological characteristics and clinical course 
of CRC in young Myanmar patients. 
 
MATERIALS AND METHODS 
This study was hospital-based descriptive 
study from January 2018 to December 2018 in 
Medical Oncology Department, YGH. Study 
population was newly diagnosed young 
colorectal cancer patients who registered at 
Medical Oncology   Department, YGH within 
study period. Inclusion criteria were patients 
with histologically proven adenocarcinoma of 
colorectal cancer under 40 years of age and 
exclusion criteria included patients with 
concomitant or prior malignancy patients with 
other histological types rather than 
adenocarcinoma and patients ≥ 40 years of 
age. Patient chart and data, imaging facilities 
(USG, CXR, CT scan), colonoscopy, CEA 
level, baseline investigations (liver function, 
renal function, complete blood count and 
cardiac function including ECHO) were 
recorded. Types of treatment obtained 
(Surgery, Radiotherapy, Chemotherapy or 
best supportive care) were noted. Responses 
were assessed after 6th cycle and end of 
chemotherapy. Data collection was done by 
proforma and data entry, data clean up, data 
summarization and data analysis was carried 
out by computer using statistical package for 
social science (SPSS) software version 22. 
Descriptive and summary statistics were 
carried out.   
 
RESULTS 
Among 408 CRC patients registered at 
Medical Oncology Department, Yangon 
General Hospital, 78 patients (19.12%) were 
diagnosed before 40 years of age. According 
to inclusion and exclusion criteria, 62 patients 
(26 colon cancer and 36 rectal cancer patients) 
were included in this study. The mean age of 
young colon cancer was 29.69 years and the 
mean age of young rectal cancer was 29.53 
years. The youngest age was 18 years for 
colon cancer and 14 years for rectal cancer. 
According to age group, both colon and rectal 
cancers were commonly occurred in the age 
group of 30-39 years. The male: female ratio 
was 1.2: 1. Among 62 patients, 9 patients had 
family history of cancer. The most frequent 
presenting symptom was abdominal pain 
(29%). Other symptoms were tenesmus 
(19.4%), constipation (16.1%), bleeding per 
rectum (16.1%), change in bowel habit 
(8.1%), abdominal mass (8.1%) and 














































(54.8%) of patients showed normal CEA level 
and (45.2%) had elevated CEA level. The 
most common location of tumor was rectum 
(45.2%). Second most common location was 
sigmoid colon and ascending colon (14.5%) 
each. Recto-sigmoid junction tumor was 
found in (12.9%) and tumor at descending 
colon was occurred in (3.2%).  
 
 




































































The most presenting stage was stage 
III (43.5%), followed by stage II (30.6%) and 
stage IV (25.8%). There was no stage I in this 
study. Adenocarcinoma (unspecified) (58.1%) 
was the most common histopathological 
subtype, followed by adenocarcinoma 
(mucinous) (30.6%) and signet ring cell 
carcinoma (11.3%). (51.6%) had moderately 
differentiated histology, (43.55%) had poorly 
differentiated histology and (4.8%) showed 
well differentiated histology. 
Various surgical procedures were 
noted; hemicolectomy in 19 patients, 
palliative colostomy in 19 patients, ARR in 10 
patients, laparoscopic ARR in 1 patient, APR 
in 4 patients and laparoscopic APR in 3 
patients, Hartmann’s operation in 5 patients 
and debulking surgery (ARR with 
appendectomy with right salpingo-
oophrectomy for carcinoma of rectosigmoid 
junction with right ovarian metastasis) in 1 
patient. Among 36 young rectal cancer 
patients in this study, 27 patients (75%) were 
treated with radiotherapy with curative intent 
and 9 patients (25%) had no radiotherapy 
since 6 patients had already stage IV at the 
time of presentation, 1 had complication such 
as intestinal obstruction and 2 patients 
progressed to stage IV before radiotherapy. 
Among 62 patients, 9 patients received 
neoadjuvant chemotherapy, 38 patients were 
treated with adjuvant chemotherapy and 15 
patients were given palliative chemotherapy. 
Various chemotherapy regimens were given; 
modified de Gramont regimen in 6 patients, 
FOLFOX  regimen in 54 patients and 
CAPEOX regimen in 2 patients.  
Among 38 patients who received 
adjuvant chemotherapy, 2 out of 17 stage II 
patients and 8 out of 20 stage III patients were 
found to have local recurrence and 4 out of 20 
stage III patients had distant recurrence during 
adjuvant chemotherapy. Remaining 24 
patients had no recurrence. These 24 patients 
were reassessed 6 months after completion of 
adjuvant chemotherapy and the result showed 
16 patients had no recurrence, 6 patients had 
locoregional recurrence and 2 patients had 
distant recurrence. Among 9 patients who 
received neoadjuvant chemotherapy, 3 
patients had partial response, 2 had stable 
disease and 4 had progressive disease. Among 
them, only 1 patient was performed ARR after 
neoadjuvant therapy. 4 patients were not done 
surgery due to progressive disease. 2 patients 
were planning for operation and 2 patients 
were receiving neoadjuvant radiotherapy at 
the end of study. Among 15 stage IV patients, 
who received palliative chemotherapy, 2 
patients had partial response and remaining 13 




Colorectal cancer (CRC) is the most 
common malignancy in the gastrointestinal 
tract and the third leading cause of cancer 
associated death in the world. Sporadic 
colorectal cancer is traditionally diagnosed 
after the sixth decades of life, and current 
recommendations for surveillance include 
only patients older than 50 years of age. 
However, increasing incidence of young-onset 
colorectal cancer was noted in many regions 
across the globe.5 Moreover, Vuik FER et al., 
(2019) study also stated CRC incidence rises 
among young adults in Europe.6 
This study was a hospital based 
descriptive study of young colorectal cancer 
younger than 40 years of age who were 
registered in Medical Oncology Department 
of YGH during the period of January 2018 to 
December 2018. During this study period, 
total 408 new cases of colorectal cancer were 
registered in Medical Oncology Department, 
YGH. Among them, 78 cases were younger 
than 40 years (19.12% of all colorectal cancer 
cases) (YGH cancer registry, 2018). 
According to inclusion and exclusion 
criteria, 62 cases were enrolled in this study 
group. There were 26 young colon cancer 
patients (41.9%) and 36 young rectal cancer 
patients (58.1%). This study included 
demographic data, clinical presentation, 
histopathological characteristics, anatomical 
distribution, presenting stage, treatment 
modalities given and outcomes in terms of 
response to treatment, 6 month disease free 
survival and death. 
 
In this study, the mean age of young 
colon cancer was 29.69 years and the mean 
age of young rectal cancer was 29.53 years. 
According to age group, both colon and rectal 
cancers were commonly occurred in the age 
group of 30-39 years. The male: female ratio 
was 1.2: 1 and therefore male preponderance 
was observed. In Haleshappa et al., (2017) 
study, the median age of the study cohort was 
33 years (12–40). Majority of the patients 
belonged to the age group of 30–39 years and 
there was a male preponderance and it was 
nearly similar with this study.7 
In Bouassida et al., (2012) study, the 
most frequent presenting complaints were 
abdominal pain (52%), per-anal bleeding 
(22.5%), change in bowel habit (17.5%) and 
constipation (17.5%).8 In this study, the most 
frequent presenting symptom was abdominal 
pain which was occurred in 18 out of 62 
patients (29%). Other symptoms were 
tenesmus in 12 patients (19.4%), constipation 
in 10 patients (16.1%), bleeding per rectum in 
10 patients (16.1%) and change in bowel habit 
in 5 patients (8.1%). 
In Jieun Lee et al., (2016) study, the 
tumor location of young colorectal cancer was 
the following in decreasing order; rectum 
(37%) of patients, sigmoid colon (24%), 
ascending colon (21%), transverse colon 
(10%), recto-sigmoid junction (3%) and 
descending colon (2%).9 In this study, the 
most common location of tumor was rectum 
which was found in 28 patients (45.2%). 
Second most common location was sigmoid 
colon and ascending colon (14.5%) each. 
Recto-sigmoid junction tumor was found in 8 
patients (12.9%) and tumor at descending 
colon was occurred in 2 patients (3.2%). 
Saluja et al., (2014) stated that the 
most common presenting stage was stage III 
(45%) followed by stage IV (30%), stage II 
(20%) and stage I (5%).10 Among 62 patients 
in this study, the most presenting stage was 
stage III which was found in 27 patients 
(43.5%), followed by stage II which was 
found in 19 patients (30.6%) and stage IV 
which was noted in 16 patients (25.8%). 
There was no stage I young colorectal cancer 
patient in this study. This will be due to 
relative lack of knowledge and awareness to 
CRC symptoms compared with patients in the 
developed countries. 
In the study, adenocarcinoma 
(unspecified) (58.1%) was the most common 
histopathological subtype, followed by 
adenocarcinoma (mucinous) (30.6%) and 
signet ring cell carcinoma (11.3%). In study 
of different clinical characteristics in sporadic 
young-age onset colorectal cancer in Korea, 
adenocarcinoma (unspecified) was also the 
most common histopathological type found in 
(76.2%), followed by adenocarcinoma 
(mucinous) (19%) and signet ring cell 
carcinoma (4.8%).9 
In this study, 32 patients (51.6%) had 
moderately differentiated histology, 27 
patients (43.55%) had poorly differentiated 
histology and only 3 patients (4.8%) showed 
well differentiated histology. Rui Wang et al., 
(1988-2011) stated that moderately 
differentiated histology was found in 63.9% 
of patients, poorly differentiated in 25.9% and 
well differentiated histology in 8.1%.11 
Surgery is the only universally 
accepted potentially curative treatment for 
colorectal cancer. Fifty to sixty percent of 
patients who undergo successful surgery for 
colon carcinoma have residual micro-
metastatic disease. Systemic chemo-therapy is 
given in an effort to clear micrometastatic 
disease. 12 
Various surgical procedures were 
noted; hemicolectomy in 19 patients, 
palliative colostomy in 19 patients, ARR in 10 
patients, laparoscopic ARR in 1 patient, APR 
in 4 patients and laparoscopic APR in 3 
patients, Hartmann’s operation in 5 patients 
and debulking surgery (ARR with 
appendectomy with right salpingo-
oophrectomy for carcinoma of rectosigmoid 
junction with right ovarian metastasis) in 1 
patient.  
Jason et al., (2019) found that in 
contrast to colon cancer, local treatment 
failures of rectal cancer after potentially 
curative resections represent a major clinical 
problem.13 Combined modality therapy with 
RT (chemoRT) is the standard therapy for 
patients with stage II and III rectal cancer (T3, 
T4 and nodal involvement).  
Among 36 young rectal cancer 
patients in this study, 27 patients (75%) were 
treated with radiotherapy with curative intent 
and 9 patients (25%) had no radiotherapy 
since 6 patients had already stage IV at the 
time of presentation, 1 had complication such 
as intestinal obstruction and 2 patients 
progressed to stage IV before radiotherapy.  
Among 62 patients, 9 patients 
received neoadjuvant chemotherapy, 38 
patients were treated with adjuvant 
chemotherapy and 15 patients were given 
palliative chemotherapy. Various chemo-
therapy regimens were given; modified de 
Gramont regimen in 6 patients, FOLFOX  
regimen in 54 patients and CAPEOX regimen 
in 2 patients.  
The response assessment was 
performed using revised Response Evaluation 
Criteria in Solid Tumors (RECIST) guideline 
version (1.1). In total 62 patients, 38 patients 
were treated with adjuvant chemotherapy. 
Among those 38 patients, 10 patients (26.3%) 
had locoregional recurrence and 4 patients 
(10.5%) showed distant recurrence during 
adjuvant chemotherapy. Only 24 patients 
(63.2%) were noted to have no recurrence 
until the end of adjuvant chemotherapy. 
Since the study period was too short, 
the advantage of adjuvant chemotherapy was 
not clearly identified by means of survival in 
this study. Therefore, these 24 patients were 
reassessed at 6 months after completion of 
chemotherapy and it was found that 6 patients 
had locoregional recurrence and 2 patients 
showed distant recurrence. 12 stage II patients 
and 3 stage III patients showed no recurrence. 
Moreover, one stage IV patient who received 
debulking surgery followed by adjuvant 
chemotherapy had no recurrence up to 6 
months after completion of adjuvant 
chemotherapy. 
Among 9 patients who received neo-
adjuvant chemotherapy, only 1 rectal cancer 
patient, who had partial response after 
neoadjuvant therapy, was performed ARR at 
the end of my study. 4 patients were not done 
surgery due to progressive disease. 2 patients 
were planning for operation and 2 patients 
were receiving neoadjuvant radiotherapy at 
the end of study. Saluja et al., also described 
that among 18 patients of young CRC patients 
who received neoadjuvant chemotherapy only 
4 patients underwent resection. There was a 
partial response in 2 patients and stable 
disease in the other two. 
Among 16 stage IV patients, 1 patient 
had debulking surgery (ARR, appendectomy 
and right salpingo-oophrectomy) for tumor at 
recto-sigmoid junction with right ovarian 
metastasis (T3N1bM1a) followed by adjuvant 
chemotherapy (FOLFOX – 12 cycles) and 
adjuvant radiotherapy (50 Gy /25 fractions). 
This patient had no recurrence until the end of 
this study. The remaining 15 patients were 
performed palliative resection followed by 
palliative chemotherapy. 2 out of these 15 
patients (13.3%) had partial response and the 
remaining 13 patients (86.7%) had 
progressive disease following palliative 
chemotherapy. 
Progressive disease were highly 
observed in this study. It may be due to 
aggressive nature of young onset CRC. Saluja 
et al., (2014) described that young onset 
colorectal cancer had aggressive nature when 
compared to elderly population thereby 
resulting in advanced disease, which is less 
resectable at the time of presentation.10 
Moreover, Anele et al., (2019) reported that 
despite higher rates of adjuvant and neo-
adjuvant treatment, young CRC were found to 
have worse disease-free survival compared to 
older group.14 
During this study, death events were 
occurred in 13 patients (20.97% of total 
patients). They were 4 stage III patients and 9 
stage IV patients. All patients were died of 
cancer with disease progression. 
 
CONCLUSION 
In conclusion, this study provided the 
demographic distribution, different clinical 
characteristics and presentations, treatment 
modalities and different clinical outcomes of 
young colorectal cancer. Based on these 
findings, we can conclude that most patients 
are symptomatic at the time of presentation, 
with the majority having rectal bleeding and 
chronic abdominal pain. The majority of 
tumors were located in the rectum, sigmoid 
colon and ascending colon.  
The earlier the stage, the more 
curative surgery and favorable outcome occur. 
Therefore, it was very important to notify the 
early symptoms of colorectal cancer. This 
study will promote increased awareness and 
aggressive pursuit of symptoms in young 
patients.  
Incidence and prevalence of young 
colorectal cancer is rising all over the world 
and becoming a major concern. This study 
was single center study consisting of small 
number of patients so that there were many 
limitations for definite conclusion. Hopefully, 
we will have more studies on young colorectal 
cancer patients covering many Oncology 
Centers in Myanmar in the future. 
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